Precision-medicine treatment for advanced cancer in Norway
Treatments studied
Part of Cancer clinical trials.
This Phase 2 trial tries to match people with advanced cancer to targeted treatments based on their tumor’s genetic results. It may help if standard cancer treatments are no longer working or aren’t available, and if a “target” in the tumor suggests a therapy that could work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed (pathology-proven) advanced or metastatic cancer that is not responding to standard treatment, or no standard option is available.
- Your general health allows treatment (ECOG performance status 0–2).
- Your blood and organ tests are at acceptable levels (for example, enough white blood cells, hemoglobin, platelets, and enough kidney function).
- Your cancer can be measured on scans or exams (except a few specific tumor-marker-only cases like ovarian CA-125 and prostate PSA).
- You have tumor genetic results from an approved lab showing a target that matches an available targeted therapy in the study.
- You can use the study drug safely, including swallowing oral medicines if the chosen therapy is a pill, and you meet any extra “drug-specific” rules for the selected treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial matches people with advanced cancer to a targeted treatment based on a genetic (DNA) or protein (IHC) test from their tumor. It’s for cancers that are no longer responding to standard treatment or where no standard option is available.
This Phase 2 study tests atezolizumab, an immunotherapy drug, in people with advanced, incurable solid tumors whose tumor DNA/RNA suggests they may respond. The goal is to see if the treatment works better for patients selected by these lab results.
This trial helps match people with advanced, hard-to-treat cancers to targeted cancer drugs based on lab testing of their tumor. It may help if standard treatment isn’t working or isn’t available, and if your tumor has a “targetable” genetic change.
This study tests whether adjusting the dose of the immunotherapy drug atezolizumab (Tecentriq) based on its levels in your blood works well. You may be able to join if you have advanced cancer and your doctor already plans to give you this drug (alone or with other approved treatments).
This trial studies whether giving a targeted cancer medicine based on tumor genetic/protein test results can help people with advanced, incurable cancers live longer. You may be eligible if your cancer has a “potentially actionable” change on testing and you meet health and follow-up requirements.
This trial tests whether FDA-approved targeted drugs can help people with advanced cancer whose tumors have specific gene changes. It aims to match your tumor's unique genetic profile to a drug that may work better for you.
Hear when a new Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.